Compass Therapeutics, Inc. (NASDAQ: CMPX) reported a net loss of $18.32 million, or $0.10 per share, for the first quarter of 2026, compared with a $16.63 million loss, or $0.12 per share, in the same quarter a year earlier. The widening loss reflects a 41% increase in general and administrative expenses to $6.9 million, driven by pre‑commercialization costs and higher stock‑based compensation, as well as continued investment in clinical development. R&D spending rose as the company advanced its lead bispecific antibody, tovecimig, through a positive Phase 2/3 study in biliary tract cancer, and expanded other programs such as CTX‑8371 and CTX‑10726.
Compass Therapeutics’ cash balance stood at $195 million as of March 31, 2026, giving the company a runway that extends into 2028. The strong liquidity position supports ongoing clinical activities and positions the company to pursue a Biologics License Application for tovecimig later in 2026, following its Orphan Drug Designation by the FDA.
Thomas Schuetz, MD, PhD, CEO, said, "We recently announced positive data from our Phase 2/3 study of tovecimig and look forward to meeting with the FDA before filing a BLA later this year. Most patients with BTC have no approved therapeutic option in the second line setting. Tovecimig, with its strong response rate, striking progression benefit and impact on overall survival would be a compelling treatment alternative for these patients." The comment underscores the company’s focus on translating clinical success into regulatory milestones.
The earnings were in line with analyst expectations, with consensus estimates of a $0.10 loss per share. While the net loss increased year‑over‑year, the loss per share narrowed, reflecting a modest increase in diluted shares outstanding and the company’s continued emphasis on long‑term pipeline development.
Investors have historically reacted to Compass Therapeutics’ earnings releases with attention to clinical progress and cash runway. The positive data for tovecimig and the company’s robust liquidity are key tailwinds that support confidence in its future prospects, while the higher G&A expenses signal ongoing investment in pre‑commercial activities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.